Subcutaneous ICD therapy results in a similar quality of life compared with transvenous ICD therapy during both short- and long-term follow-up

Abstract Funding Acknowledgements Type of funding sources: Private grant(s) and/or Sponsorship. Main source(s): Boston Scientific Medical device company St. Paul, Minnesota, USA Introduction The PRAETORIAN trial showed that the subcutaneous implantable cardioverter defibrillator (S-ICD) is noninferior to transvenous ICD (TV-ICD) with respect device-related complications and inappropriate shocks in a conventional population. It unknown whether there difference quality life (QoL) between two patient groups. generator size implant location differ both devices. This may cause variation mental health status pain perception treatment arms, particular older patients, patients low BMI, females. Purpose prespecified analysis compares impact S-ICD TV-ICD on QoL. Methods In trial, 849 were randomised (n=426) or (n=423) therapy. QoL was prospectively measured at baseline, discharge 12 30 months after implant, by measuring cardiac-specific physical functioning Duke Activity Status Index (DASI) psychological well-being 36-Item Short Form Health Survey (SF-36, divided 8 subscales). Patients who completed questionnaires baseline included this analysis. At each time point mean change score from calculated. Subgroups made based age (tertiles, < 58, 58-67 >67 years), BMI categories (<25, 25-30, ≥30 kg/m2) sex. these subgroups, we only looked differences arms. Treatment effects, 95% CIs interactions calculated regression models. Results A total 823/849 baseline. Questionnaires also (92%), (85%) (69%). There no arms any (p>0.05, figure). Age, sex not associated SF-36 subscale bodily (p=0.73, 0.72 0.92 respectively), (p=0.15, 0.39 0.76) months. Similar results seen Conclusion first implant. addition, These confirm good alternative for TV-ICD.